Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

340 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Prognostic and predictive markers for the new immunotherapies.
Mahoney KM, Atkins MB. Mahoney KM, et al. Among authors: atkins mb. Oncology (Williston Park). 2014 Nov;28 Suppl 3:39-48. Oncology (Williston Park). 2014. PMID: 25384886 Review.
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Gibney GT, Weiner LM, Atkins MB. Gibney GT, et al. Among authors: atkins mb. Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5. Lancet Oncol. 2016. PMID: 27924752 Free PMC article. Review.
PD-1 as a potential target in cancer therapy.
McDermott DF, Atkins MB. McDermott DF, et al. Among authors: atkins mb. Cancer Med. 2013 Oct;2(5):662-73. doi: 10.1002/cam4.106. Epub 2013 Jul 21. Cancer Med. 2013. PMID: 24403232 Free PMC article. Review.
Immune therapy for kidney cancer: a second dawn?
McDermott DF, Atkins MB. McDermott DF, et al. Among authors: atkins mb. Semin Oncol. 2013 Aug;40(4):492-8. doi: 10.1053/j.seminoncol.2013.05.008. Semin Oncol. 2013. PMID: 23972713 Review.
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK, Atkins M. Philips GK, et al. Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Int Immunol. 2015. PMID: 25323844 Review.
PD-L1 expression in nonclear-cell renal cell carcinoma.
Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S. Choueiri TK, et al. Among authors: atkins mb. Ann Oncol. 2014 Nov;25(11):2178-2184. doi: 10.1093/annonc/mdu445. Epub 2014 Sep 5. Ann Oncol. 2014. PMID: 25193987 Free PMC article.
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB, Clark JI, Quinn DI. Atkins MB, et al. Ann Oncol. 2017 Jul 1;28(7):1484-1494. doi: 10.1093/annonc/mdx151. Ann Oncol. 2017. PMID: 28383639 Review.
Advances in immunotherapy for melanoma.
Redman JM, Gibney GT, Atkins MB. Redman JM, et al. Among authors: atkins mb. BMC Med. 2016 Feb 6;14:20. doi: 10.1186/s12916-016-0571-0. BMC Med. 2016. PMID: 26850630 Free PMC article. Review.
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S. Callea M, et al. Among authors: atkins mb. Cancer Immunol Res. 2015 Oct;3(10):1158-64. doi: 10.1158/2326-6066.CIR-15-0043. Epub 2015 May 26. Cancer Immunol Res. 2015. PMID: 26014095 Free PMC article.
Treatment selection for patients with metastatic renal cell carcinoma.
Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S. Atkins MB, et al. Cancer. 2009 May 15;115(10 Suppl):2327-33. doi: 10.1002/cncr.24231. Cancer. 2009. PMID: 19402069 Free PMC article. Review.
340 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback